Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Revance Therapeutics Inc's Business Segments
Revance Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Product revenue net
Total Revenue
$ 60
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product revenue net98.2%
- RHA Collection of dermal fillers50.9%
- DAXXIFY47.3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product revenue net | $ 59 | 98.2% |
| RHA Collection of dermal fillers | $ 31 | 50.9% |
| DAXXIFY | $ 28 | 47.3% |
Revenue by Product & Service Category - FY
- Product98.2%
- RHA® Collection of dermal fillers50.9%
- DAXXIFY47.3%
- Collaboration Revenue1.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 59 | 98.2% |
| RHA® Collection of dermal fillers | $ 31 | 50.9% |
| DAXXIFY | $ 28 | 47.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Revance Therapeutics Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Product revenue net98.2%
- RHA Collection of dermal fillers50.9%
- DAXXIFY47.3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product revenue net | $ 59 | 98.2% |
| RHA Collection of dermal fillers | $ 31 | 50.9% |
| DAXXIFY | $ 28 | 47.3% |
Description of Revance Therapeutics Inc
Revance Therapeutics Inc is a biotechnology company that specializes in developing and commercializing innovative therapies for cosmetic and therapeutic applications. The company was founded in 1999 and is headquartered in Newark, California.
Revance Therapeutics Inc's main focus is on developing a new generation of neuromodulators that has the potential to revolutionize the field of aesthetics and therapeutics. Neuromodulators are medications that can selectively disrupt nerve transmission, leading to muscle relaxation and paralysis. These medications are commonly used for cosmetic treatments such as smoothing out wrinkles and fine lines, but they can also treat various medical conditions such as dystonia, spasticity, and migraines.
The core technology platform of Revance Therapeutics Inc is its proprietary peptide technology called RT00 RT002 is a novel form of botulinum toxin type A that has been formulated to have a longer-lasting effect and a more targeted delivery. It has been shown to have a high degree of efficacy, durability, and safety, making it a promising alternative to older neuromodulators. Revance Therapeutics Inc has filed for regulatory approval in the United States, Europe, and Canada for RT002 as both a cosmetic therapy and a therapeutic agent.
In addition to its lead product, Revance Therapeutics Inc is also developing other products in its pipeline, including a topical formulation of RT002 for at-home use, and a dermal filler product that uses a novel approach to achieve long-lasting effects.
The company's management team includes seasoned executives and scientists with extensive experience in the biotechnology industry. Its board of directors includes experts in regulatory affairs, finance, and business development.
Revance Therapeutics Inc is at the forefront of innovation in the field of neuromodulators, and its commitment to bringing safe and effective treatments to patients and consumers has earned it a reputation as a rising star in the biotechnology industry.
Revance Therapeutics Inc's main focus is on developing a new generation of neuromodulators that has the potential to revolutionize the field of aesthetics and therapeutics. Neuromodulators are medications that can selectively disrupt nerve transmission, leading to muscle relaxation and paralysis. These medications are commonly used for cosmetic treatments such as smoothing out wrinkles and fine lines, but they can also treat various medical conditions such as dystonia, spasticity, and migraines.
The core technology platform of Revance Therapeutics Inc is its proprietary peptide technology called RT00 RT002 is a novel form of botulinum toxin type A that has been formulated to have a longer-lasting effect and a more targeted delivery. It has been shown to have a high degree of efficacy, durability, and safety, making it a promising alternative to older neuromodulators. Revance Therapeutics Inc has filed for regulatory approval in the United States, Europe, and Canada for RT002 as both a cosmetic therapy and a therapeutic agent.
In addition to its lead product, Revance Therapeutics Inc is also developing other products in its pipeline, including a topical formulation of RT002 for at-home use, and a dermal filler product that uses a novel approach to achieve long-lasting effects.
The company's management team includes seasoned executives and scientists with extensive experience in the biotechnology industry. Its board of directors includes experts in regulatory affairs, finance, and business development.
Revance Therapeutics Inc is at the forefront of innovation in the field of neuromodulators, and its commitment to bringing safe and effective treatments to patients and consumers has earned it a reputation as a rising star in the biotechnology industry.
Revance Therapeutics Inc. is a pioneering biopharmaceutical company that develops and commercializes advanced products and solutions within both aesthetic and therapeutic segments of medicine. Their focus is on addressing unmet medical needs through innovative technologies, with a core emphasis on neurotoxins, injectable fillers, and various therapeutic applications.
Segments
1. Aesthetics
Revances aesthetic segment encompasses a comprehensive portfolio of products that focus on cosmetic enhancements. This segment primarily includes:
- Neurotoxins: These are injectable agents used for smoothing out facial wrinkles and fine lines. Revances neurotoxin products are designed to provide lasting results, often exceeding the duration of competing products.
- Injectable Fillers: This category includes products designed to restore volume, contour the face, and improve skin texture. The fillers are utilized in various cosmetic procedures to enhance facial features.
Therapeutics
In the therapeutic segment, Revance specializes in treatments for various medical conditions employing its innovative products, including:
- Chronic Migraine Treatment: Targeting adults suffering from chronic migraines, with formulations intended to provide not just symptomatic relief but also preventative care.
- Spasticity and Dystonia: These products aim to alleviate muscle stiffness and involuntary muscle contractions in conditions such as cervical dystonia and upper limb spasticity.
Products
1. Daxibotulinumtoxin A for Injection (DAXI)
DAXI is a key breakthrough product and is recognized for its extended duration of effect. Approved by the FDA, it is used to reduce the appearance of wrinkles and fine lines, making it a popular choice among both patients seeking cosmetic improvements and practitioners looking for reliable results.
RHA (Resilient Hyaluronic Acid) Fillers
Revance offers a sophisticated line of injectable fillers branded as RHA. These dermal fillers are made from resilient hyaluronic acid that mimics the natural movement of facial tissues. They are designed to adapt to facial dynamics, offering a more natural aesthetic outcome while effectively restoring lost volume and smoothing wrinkles.
Botulinum Toxin Type A for Therapeutic Use
Apart from its cosmetic applications, Revance is also expanding the use of Botulinum Toxin Type A in therapeutic fields. It has potential applications for treating chronic migraines, alleviating neck pain, and managing other neuromuscular disorders.
Services
1. Clinical Studies
Revance possesses a robust research and development framework. The company conducts rigorous clinical studies aimed at testing the safety and efficacy of its products, ensuring that their offerings are backed by scientific validation.
Physician Training and Education
Recognizing the importance of proper product administration, Revance provides extensive training programs for healthcare professionals. Through these educational initiatives, healthcare providers are equipped with the necessary skills and knowledge to administer Revance products effectively.
Patient Support Services
Revance offers comprehensive patient support through a dedicated customer care team. This service is designed to assist patients with inquiries related to the companys products, including education on treatment options, assistance with billing processes, and guidance on insurance reimbursement.
Conclusion
Revance Therapeutics Inc. stands at the forefront of biopharmaceutical innovation, offering a diverse portfolio of aesthetic and therapeutic products and services. With a clear commitment to enhancing patient outcomes and addressing unmet medical needs, Revance continues to make significant strides in both rejuvenating patients’ appearances and providing therapeutic solutions for chronic medical conditions. Through its various segments, products, and support services, Revance is well-positioned to meet the evolving needs of patients and healthcare providers alike.
Segments
1. Aesthetics
Revances aesthetic segment encompasses a comprehensive portfolio of products that focus on cosmetic enhancements. This segment primarily includes:
- Neurotoxins: These are injectable agents used for smoothing out facial wrinkles and fine lines. Revances neurotoxin products are designed to provide lasting results, often exceeding the duration of competing products.
- Injectable Fillers: This category includes products designed to restore volume, contour the face, and improve skin texture. The fillers are utilized in various cosmetic procedures to enhance facial features.
Therapeutics
In the therapeutic segment, Revance specializes in treatments for various medical conditions employing its innovative products, including:
- Chronic Migraine Treatment: Targeting adults suffering from chronic migraines, with formulations intended to provide not just symptomatic relief but also preventative care.
- Spasticity and Dystonia: These products aim to alleviate muscle stiffness and involuntary muscle contractions in conditions such as cervical dystonia and upper limb spasticity.
Products
1. Daxibotulinumtoxin A for Injection (DAXI)
DAXI is a key breakthrough product and is recognized for its extended duration of effect. Approved by the FDA, it is used to reduce the appearance of wrinkles and fine lines, making it a popular choice among both patients seeking cosmetic improvements and practitioners looking for reliable results.
RHA (Resilient Hyaluronic Acid) Fillers
Revance offers a sophisticated line of injectable fillers branded as RHA. These dermal fillers are made from resilient hyaluronic acid that mimics the natural movement of facial tissues. They are designed to adapt to facial dynamics, offering a more natural aesthetic outcome while effectively restoring lost volume and smoothing wrinkles.
Botulinum Toxin Type A for Therapeutic Use
Apart from its cosmetic applications, Revance is also expanding the use of Botulinum Toxin Type A in therapeutic fields. It has potential applications for treating chronic migraines, alleviating neck pain, and managing other neuromuscular disorders.
Services
1. Clinical Studies
Revance possesses a robust research and development framework. The company conducts rigorous clinical studies aimed at testing the safety and efficacy of its products, ensuring that their offerings are backed by scientific validation.
Physician Training and Education
Recognizing the importance of proper product administration, Revance provides extensive training programs for healthcare professionals. Through these educational initiatives, healthcare providers are equipped with the necessary skills and knowledge to administer Revance products effectively.
Patient Support Services
Revance offers comprehensive patient support through a dedicated customer care team. This service is designed to assist patients with inquiries related to the companys products, including education on treatment options, assistance with billing processes, and guidance on insurance reimbursement.
Conclusion
Revance Therapeutics Inc. stands at the forefront of biopharmaceutical innovation, offering a diverse portfolio of aesthetic and therapeutic products and services. With a clear commitment to enhancing patient outcomes and addressing unmet medical needs, Revance continues to make significant strides in both rejuvenating patients’ appearances and providing therapeutic solutions for chronic medical conditions. Through its various segments, products, and support services, Revance is well-positioned to meet the evolving needs of patients and healthcare providers alike.